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ABSTRACT 
Bioactive potential of apigenin derivative apigenin-7-O-glucoside related to its antifungal activity on Candida spp. 
and cytotoxic effect on colon cancer cells was studied and compared with bioactive potential of apigenin. Anti-
fungal activity was tested on 14 different isolates of Candida spp. using membrane permeability assay, measuring 
inhibition of reactive oxidative species and inhibition of CYP51 C. albicans enzyme. Cytotoxic potential of apig-
enin-7-O-glucoside was tested on colon cancer HCT116 cells by measuring cell viability, apoptosis rate and apop-
tosis- and colon cancer-related gene expression. Obtained results indicated considerable antifungal activity of 
apigenin-7-O-glucoside towards all Candida isolates. Breakdown of C. albicans plasma membrane was achieved 
upon treatment with apigenin-7-O-glucoside for shorter period of time then with apigenin. Reduction of intra- and 
extracellular reactive oxidative species was achieved with minimum inhibitory concentrations of both compounds, 
suggesting that reactive oxidative species inhibition could be a mechanism of antifungal action. None of the com-
pounds exhibited binding affinity to C. albicans CYP51 protein. Besides, apigenin-7-O-glucoside was more ef-
fective compared to apigenin in reduction of cell’s viability and induction of cell death of HCT116 cells. Treat-
ment with both compounds resulted in chromatin condensation, apoptotic bodies formation and apoptotic genes 
expression in HCT116 cells, but the apigenin-7-O-glucoside required a lower concentration to achieve the same 
effect. Compounds apigenin-7-O-glucoside and apigenin displayed prominent antifungal potential and cytotoxic 
effect on HCT116 cells. However, our results showed that apigenin-7-O-glucoside has more potent activity com-
pared to apigenin in all assays that we used. 
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INTRODUCTION 
There is a constant need for search of 
novel antifungal drugs considering the fact 
that resistance and multi-resistance occurs 
very often to synthetic drugs currently in use 
for treatment of fungal infections. In the field 
of naturally occurring substances that might 
have a potential antifungal activity, there are 
many opportunities for research. One of the 
major groups with highly potent bioactive 
compounds is a group of flavonoids which is 
promising regarding discovering new antifun-
gal compounds and compounds capable to re-
duce the incidence of different cancer types 
(Wesołowska, 2011; Kandaswami et al., 
2005). 
Literature data suggest that there is a link 
between pathogen fungus present in intestinal 
mycobiota and the incidence of adenomas. In 
particular, Luan et al. (2015) showed that the 
presence of pathogen fungus in intestine may 
be common among patients with adenomas. 
Candida was one of the genera with relatively 
high abundance present in adenomas (7 %) 
and adjacent tissue samples (1 %). More than 
80 % of sporadic colorectal cancer (CRC) 
cases were induced by colorectal adenoma 
(Ullman and Itzkowitz, 2011). This type of 
cancer is the third most common cancer in 
males and the second most common cancer in 
females worldwide; over 1.2 million CRC di-
agnoses and 608,700 CRC deaths were rec-
orded in 2008 (Jemal et al., 2010). Advanced 
adenomas can further develop into carcinoma. 
Although, during the past decade, colorectal 
screening leads to decreased incidence and 
mortality (Jorgensen and Knudtson, 2015), 
there is a constant demand for development of 
novel drugs and identification of natural com-
pounds with antitumor activity.  
Apigenin-7-O-glucoside (AP7Glu) is a 
stable natural flavonoid, with better solubility 
compared to other flavonoids such as apig-
enin. They both have similar anti-inflamma-
tory capacity (Kowalski et al., 2005). AP7Glu 
has multiple biological activities and is cur-
rently prescribed to treat inflammatory dis-
eases such as upper respiratory infections 
(Bhaskaran et al., 2010). It was recently 
shown that AP7Glu possessed anxiolytic po-
tential in rats, comparable to the reference 
drugs apigenin and diazepam (Kumar and 
Bhat, 2012). Apigenin is a non-toxic and non-
mutagenic flavone subclass of flavonoids, 
present in fruits and vegetables (cardoon, cel-
ery, artichoke, parsley etc.), some of which 
are widely marketed as dietary and herbal 
supplements (Sharma et al., 2014). Apigenin 
has received considerable attention due to its 
significant anticancer, antiviral, antibacterial, 
antioxidant, pro-apoptotic and anti-inflamma-
tory effects (Kanazawa et al., 2006; Cai et al., 
2011). 
The aim of this study was to bring new in-
sight into bioactive potential of apigenin de-
rivative apigenin-7-O-glucoside, related to its 
antifungal activity and cytotoxic effect on co-
lon cancer cells and to compare it with bioac-
tive potential of apigenin. Beside their com-
parison, our intent was to get better insight of 
potential dual effect of tested bioactive com-
pounds necessary for different aspects of co-
lon cancer treatment.  
 
MATERIAL AND METHODS 
Apigenin-7-O-glucoside and apigenin 
Flavonoid compounds AP7Glu and apig-
enin were commercially available (Extrasyn-
these, France). 
 
Anti-candidal activity 
Microbial culture conditions 
Eleven strains of C. albicans were used in 
the experiments, including isolates of C. 
krusei, C. glabrata and C. tropicalis. Nine of 
the strains used were clinical isolates and two 
were reference strains Candida albicans 
ATCC 10231 and Candida tropicalis ATCC 
750. All clinical isolates were obtained by 
rubbing a sterile cotton swab over oral mu-
cosa from patients at the Department of Pedi-
atric and Preventive Dentistry, Faculty of 
Dental Medicine, University of Belgrade, 
Serbia, upon obtaining informed written con-
sent. Strains of Candida spp. were maintained 
on Sabourand Dextrose Agar (Merck, Ger-
many) at 4 °C and subcultured once a month. 
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Identification of Candida spp. was done using 
biochemical profiling with API 20C and with 
CHROMagar plates.  
Microdilution method 
Minimum inhibitory (MIC) and minimum 
fungicidal (MFC) concentrations were deter-
mined by microdilution method in 96 well mi-
crotitre plates, described by Douk et al. 
(1995) and EUCAST (2002). As a positive 
control commercial mycotic drug ketocona-
zole (Sigma-Aldrich, St. Louis, MO) was 
used. 
 
Insights in the mode of antimicrobial action 
of AP7Glu and apigenin 
Nucleotide leakage –  
membrane permeability assay 
The effect of apigenin-7-O-glucoside on 
membrane permeability (nucleotide leakage) 
was evaluated according to Tang et al. (2008) 
with some modifications and compared to ef-
fect of apigenin. The culture of C. albicans 
475/15 incubated overnight at 37 °C was 
washed and resuspended in 10 mM PBS (pH 
7.4), reaching the final density of 108 CFU/ 
ml. Strain was incubated with the target mol-
ecules at the 1½ MICs for different time inter-
vals: 0, 15, 30, 45 and 60 min; C. albicans in-
cubated with 10 mM PBS (pH 7.4) was used 
as control. The mixture was filtered through 
0.22 μm pore size filter to remove the yeast 
cells. The optical density of the filtrate was 
measured at 260 nm and 280 nm with Ag-
ilent/HP 8453 UV-Visible Spectrophotometer 
Agilent Technologies, USA) at room temper-
ature (25 °C). 
Determination of extracellular and  
intracellular ROS in C. albicans 
These studies were carried out with sus-
pensions of C. albicans 475/15, supplemented 
with MICs, ½ MICs and ¼ MICs of apigenin-
7-O-glucoside and apigenin. For the nitro 
blue tetrazolium (NBT) reaction (Páez et al., 
2010) 0.4 mL of yeast suspension treated 
overnight with apigenin-7-O-glucoside and 
apigenin (OD600 nm 0.8) and 0.5 mL of 1 
mg/mL NBT were incubated for 30 min at 
37 °C. Then, 0.1 mL of 0.1 M HCl was added 
and the tubes were centrifuged at 2500 g for 
10 min, with the blue color of supernatants 
being measured at 575 nm (ROS extracellu-
lar). The separated pellets were treated with 
0.6 mL dimethyl sulfoxide (DMSO) to extract 
the reduced NBT, and finally, 0.8 mL phos-
phate saline buffer was added and OD575 nm 
was determined (ROS intracellular) using Ag-
ilent/HP 8453 UV-Visible Spectrophotometer 
(Agilent Technologies, USA). 
Investigation of binding properties of  
apigenin-7-O-glucoside and apigenin for 
CaCYP51 enzyme 
Sterol 14α-demethylase (CYP51) was 
previously isolated and kindly provided by 
Laboratory of Biomolecular Structure at Na-
tional Institute of Chemistry, Ljubljana, Slo-
venia. Binding properties were investigated 
using UV-Visible spectroscopy. Different 
concentration of investigated compounds (0, 
2, 8, 16, 32, 64, 128, 256, 300 µM) were 
mixed with CYP51 protein from Candida al-
bicans. Spectra were recorded from 350 to 
500 nm, and possible ligand-induced spectral 
changes were monitored as difference type II 
spectral responses (Zelenko et al., 2014).  
 
Cytotoxic activity 
Cell culture 
Human HCT116 (ATCC-CCL-227) colon 
cancer cells were grown in Dulbecco's Modi-
fied Eagle's medium (DMEM) supplemented 
with 10 % fetal bovine serum (FBS), 
4500 mg/L glucose, 2 mmol/L L-glutamine 
and penicillin/streptomycin (all from Invitro-
gen™, USA). The cells were maintained at 
37 °C in 5 % CO2. 
MTT assay 
HCT116 cells were seeded overnight at a 
density of 3 x 104 cells per well in 96 well 
plate. After 24 h, cells were treated with vehi-
cle DMSO and various concentrations of 
apigenin or apigenin-7-O-glucoside for 48 h. 
After incubation, the cell’s viability was de-
termined by adding MTT (3-[4, 5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) at final concentration 5 mg/ml (Merck, 
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Germany). MTT containing medium was as-
pirated after 2 h and DMSO was added to each 
well to achieve solubilization of the formazan 
crystal. The absorbance at 550 nm was rec-
orded using plate reader Infinite 200 pro 
(Tecan, Austria). 
 
Insights in the mode of cytotoxic action of 
AP7Glu and apigenin 
DAPI staining of nuclear morphological 
changes of HCT116 cells 
HCT116 cells were seeded on cover slips 
overnight at a density of 9 x 104 cells per well 
in 12 well plate. After 24 h, cells were treated 
with calculated IC50 for AP7Glu and apig-
enin, or with DMSO as a control. 48 h after 
treatment cells were fixed in 4 % paraformal-
dehyde (PFA) for 20 min at room tempera-
ture. After fixation, nuclei were stained with 
0.1 mg/ml diamino phenylindole-DAPI 
(Sigma-Aldrich, USA). Cells were visualized 
by OLYMPUS BX41 fluorescence micro-
scope (Applied Imaging Corporation, USA) 
using the fluorescence filter 330–380 nm, 
captured with 60 x magnificence. Cells were 
counted at least in four different fields with a 
total number of 200 cells. The percentage of 
apoptotic cells (apoptotic bodies) was calcu-
lated as the ratio of apoptotic cells to total 
cells counted. 
Apoptosis assay using a double staining 
method with Annexin V-FITC/PI 
Apoptosis assays were conducted using 
the APOPTEST™-FITC kit (Dako, Agilent 
Technologies, USA) according to the manu-
facturer’s instructions. The cells were treated 
with IC50 concentration for AP7Glu or apig-
enin for 48 hours or with DMSO. The cells 
were washed twice with cold PBS, resus-
pended in 1× Binding Buffer at a final number 
of 1 × 106 cells/ml and 5 μl Annexin V and 
propidium iodide (PI) were added. The cells 
were gently mixed, incubated for 10 min in 
the dark at room temperature, and analyzed by 
Partec CyFlow® Space (Partec GmbH, Ger-
many). The flow cytometer collected 100.000 
events and analysis was performed using Flo-
max 2.9 software.  
RT-PCR analysis 
Total RNA was isolated using TRI-Rea-
gent (Ambion®, Invitrogen, USA) according 
to the manufacturer's instructions. RNA was 
treated with DNase I using a DNA-Free™ kit 
(Ambion, Invitrogen, USA) and subjected to 
cDNA synthesis. Total RNA (1 μg) was re-
verse transcribed using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosys-
tems, USA) according to the manufacturer's 
protocol.  
For quantitative PCR analysis, cDNAs 
were subjected to real time PCR using Power 
SYBR Green PCR Master Mix (Applied Bio-
systems, USA) in 7500 Real Time PCR Sys-
tems (Applied Biosystems, USA).The synthe-
sized cDNAs were used as templates for am-
plification with primers specific for SOX9, 
p53, c-Myc, Cyclin D1, Bax and GAPDH.  
Primers for p53 amplification were as fol-
lows: 
5'-CCCCTCCTGGCCCCTGTCATCTTC-3' 
(forward) and  
5'-GCAGCGCCTCACAACCTCCGTCAT 
3' (reverse).  
C-Myc was amplified using primers  
5' CAAGAGGCGAACACACAACGTC3' 
(forward) and  
5' CTGTTCTCGTCGTTTCCGCAAC 3' 
(reverse).  
For Cyclin D1 amplification we have used  
5’-CCTGTCCTACTACCGCCTCA-3’ 
(forward) and  
5’-TCCTCCTCTTCCTCCTCCTC-3’ 
(reverse) primers,  
for Bax amplification we have used  
5’-TGGCAGCTGACATGTTTTCTGAC-3’ 
(forward) and  
5’-TCACCCAACCACCCTGGTCTT-3’ 
(reverse),  
for SOX9 amplification we have used 
5’- CTTCTGAACGAGAGCGAGA-3’ 
(forward) and  
5’-CTGCCCGTTCTTCACCGACTTC-3’ 
(reverse) primers.  
GAPDH was amplified with  
5′-GGACCTGACCTGCCGTCTAG-3′  
(forward) and  
5′-CCACCACCCTGTTGCTGTAG-3′  
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(reverse) to control for equivalent amounts of 
cDNA per reaction. All samples were meas-
ured in triplicate and the mean value was con-
sidered. The relative level of analyzed gene’s 
expression was determined using a compara-
tive quantification algorithm where the result-
ing ΔΔCt value was incorporated to determine 
the fold difference in expression (2−ΔΔCt). Rel-
ative mRNA level was presented as a percent-
age of mRNA expression in control cells 
treated with DMSO. 
 
Statistical analyses 
Statistical analyses were performed with 
SPSS statistical software (version 20). The 
data represents means  SEM from three in-
dependent experiments. Statistical analyses 
were performed by Student’s t-test and p 
value  0.05 was considered significant. 
 
RESULTS 
AP7Glu exhibits increased anti-candidal 
activity compare to apigenin 
Results of the anti-candidal activity of 
AP7Glu (0.05-0.2 mg/mL), apigenin (0.1-0.3 
mg/mL) and commercial drug ketoconazole 
(0.0016-0.1 mg/mL) are presented in Table 1. 
Obtained results showed that all tested strains 
were more sensitive to AP7Glu than to apig-
enin. In particular, range of MICs and MFCs 
was 0.05 - 0.10 mg/mL for AP7Glu, while 
treatment with apigenin resulted with MIC 
0.10 mg/mL and MFC 0.20 mg/mL. The most 
resistant strain to both compounds was C. 
krusei with the same values of MICs and 
MFCs (0.15 and 0.30 mg/mL, respectively). 
Positive control ketoconazole was used for 
monitoring anti-candidal activity and all spe-
cies were more sensitive to commercial drug 
when compared to tested compounds. These 
results propose that AP7Glu has more potent 
anti-candidal activity compared to apigenin.  
 
AP7Glu interferes with membrane integrity 
of C. albicans more rapidly than apigenin 
In order to evaluate the breakdown of 
plasma membrane in the presence of effective 
concentration of tested compounds, a mem-
brane permeability assay was performed. To-
tal nucleotide leakage from cells of C. albi-
cans was observed as a function of incubation 
time with AP7Glu and apigenin. At optical 
density at 260 and 280 nm, treatment with 
AP7Glu increased absorbance more pro-
foundly than treatment with apigenin (Figure 
1). Ketoconazole did not induce membrane 
breakdown at tested concentration. Absorb-
ance of the control samples was not changed 
during the time.  
Obtained results for nucleotide leakage 
are a good indicator of compromised mem-
brane integrity which implies that both apig-
enin and AP7Glu might directly act on the cell 
membrane surface inducing its rupture and re-
lease of intracellular genetic material. How-
ever, AP7Glu demonstrated more disturbing 
effect on C. albicans plasma membrane com-
pared to apigenin. 
 
AP7Glu has higher potential to inhibit  
extra- and intracellular ROS production of 
C. albicans compared to apigenin 
C. albicans is capable of generating sig-
nificant amounts of ROS which is in correla-
tion with its ability to invade host tissue by 
provoking oxidative damage in host cells at 
MIC and subMIC concentrations (Schröter et 
al., 2000), ROS can react with polyunsatu-
rated fatty acids in cellular membranes, 
sulfhydryl bonds in proteins and nucleotides, 
and therefore induce tissue injury in yeast in-
fections (Machlin and Bendich, 1987; Nishi-
kawa et al., 1997). We analyzed intracellular 
and extracellular ROS production by C. albi-
cans in the presence of AP7Glu, apigenin and 
commercial antifungal drug ketoconazole. 
The results indicated decreasing amounts of 
extracellular and intracellular ROS in the 
presence of AP7Glu and apigenin which was 
shown to be dose-dependent (Figure 2A, B). 
The similar pattern was noted for extracellular 
EXCLI Journal 2017;16:795-807 – ISSN 1611-2156 
Received: March 23, 2017, accepted: May 18, 2017, published: May 23, 2017 
 
 
800 
ROS, except that intracellular ROS was inhib-
ited more profoundly than extracellular ROS 
with both compounds at MIC values. Treat-
ment with ketoconazole did not cause changes 
neither in extracellular nor in intracellular 
ROS levels. AP7Glu and apigenin possessed 
similar activity, highlighting AP7Glu as more 
potent ROS inhibitor at lower concentration. 
 
AP7Glu and apigenin do not show binding 
affinities to candidal CYP51 protein 
CYP51 is enzyme essential for Candida 
albicans involved in ergosterol biosynthetic 
pathway, and it’s main target for azole anti-
fungal drugs (Kelly et al., 2003; Warrilow et 
al., 2010). In this study we found that none of 
the tested compounds bound to CYP51 pro-
tein from C. albicans (data not shown), while 
ketoconazole has mode of action which in-
volves CYP51 inhibition since it bounds can-
didal enzyme with Kd CaCYP51 < 0.05 µM, 
but it also showed affinity towards human 
protein with Kd hCYP51 < 0.05 µM. This re-
sult indicated different mechanism of antican-
didal activity of AP7Glu and apigenin in com-
parison to available antifungal azole drugs 
and draws attention to the unselective binding 
affinities of ketoconazole. 
 
 
  
 
 
Table 1: Activity of apigenin (AP), apigenin-7-O-glucoside (AP7Glu) and a reference compound keto-
conazole against Candida strains in microdilution assay 
Fungi  
strains 
AP AP7Glu Ketoconazole 
MIC MFC MIC MFC MIC MFC 
C. albicans ATCC  0.10±0.01c 0.20±0.02c 0.05±0.001b 0.10±0.01b 0.0016±0.001a 0.0062±0.001a 
C. albicans 475/15 0.10±0.02c 0.15±0.02c 0.05±0.001b 0.05±0.001b 0.0031±0.001a 0.0062±0.002a 
C. albicans 10/15 0.10±0.01b 0.20±0.02c 0.10±0.01b 0.10±0.01b 0.0031±0.002a 0.05±0.002a 
C. albicans 15/15 0.10±0.02c 0.15±0.02b 0.05±0.001b 0.10±0.01a 0.0031±0.002a 0.1±0.001a 
C. albicans 16/15 0.10±0.01c 0.20±0.01c 0.05±0.001b 0.05±0.001a 0.0031±0.001a 0.1±0.001b 
C. albicans 17/15 0.10±0.02c 0.20±0.02c 0.05±0.002b 0.10±0.01b 0.0016±0.002a 0.05±0.01a 
C. albicans 7/15 0.10±0.01c 0.20±0.02b 0.05±0.002b 0.10±0.01a 0.0031±0.001a 0.1±0.002a 
C. albicans 13/15 0.10±0.02c 0.15±0.01c 0.05±0.001b 0.10±0.03b 0.0016±0.001a 0.05±0.002a 
C. albicans 574/14 0.10±0.01c 0.20±0.02c 0.05±0.001b 0.05±0.001a 0.0031±0.001a 0.1±0.001b 
C. albicans 27/15 0.10±0.01c 0.15±0.01b 0.05±0.02b 0.10±0.01a 0.0031±0.001a 0.1±0.01a 
C. albicans 11/15 0.10±0.01b 0.20±0.02b 0.10±0.01b 0.10±0.03a 0.0031±0.002a 0.1±0.01a 
C. krusei MN13 0.15±0.02b 0.30±0.02c 0.15±0.02b 0.20±0.01b 0.0016±0.001a 0.0032±0.002a 
C. glabrata MN12 0.10±0.02c 0.20±0.01c 0.05±0.001b 0.10±0.01b 0.0016±0.001a 0.0062±0.002a 
C. tropicalis ATCC 0.10±0.02c 0.20±0.03c 0.05±0.001b 0.10±0.02b 0.0016±0.002a 0.0062±0.002a 
MIC – minimum inhibitory concentration, MFC – minimum fungicidal concentration. The results are ex-
pressed in mg/mL. 
Values are expressed as means ± SD. In each row, different letters mean significant differences be-
tween samples (p < 0.05). MIC and MFC values of the compounds are compared separately for each 
of the fungal strain tested.
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Figure 1: Nucleotide leakage in Candida albicans 
cells during treatment with apigenin, apigenin-7-
O-glucoside and ketoconazole at 1½ MIC concen-
trations (0.15 mg/mL, 0.075 mg/mL and 0.00465 
mg/mL, respectively) reported with absorbance 
on 260nm (A) and 280nm (B), untreated C. albi-
cans cells were used as control. 
 
 
AP7Glu reduce viability of colon cancer 
cells more than apigenin 
The effect of AP7Glu on the HCT116 co-
lon cancer cell’s viability was examined by 
the MTT assay and compared to the effect of 
apigenin. Cells were treated with various 
doses of AP7Glu or apigenin and then cell’s 
viability were tested 48 h after treatment. As 
shown in Figure 3, both AP7Glu and apigenin 
led to reduction in cell’s viability in a dose-
dependent manner. Moreover, the cytotoxic 
effect of AP7Glu was approximately 4-fold 
stronger compared to apigenin. In particular, 
determined IC50 values for apigenin and 
AP7Glu were 62 and 15 µM, respectively.  
Figure 2: Percentage of extracellular (eROS) and 
intracellular (iROS) inhibition of reactive oxygen 
species in C. albicans cells treated with apigenin 
(A) and apigenin-7-O-glucoside (B) at MIC, ½ 
MIC and ¼ MIC concentrations. Ketoconazole did 
not cause any changes in ROS levels, data not 
shown. 
Figure 3: The effect of apigenin and AP7Glu on 
HCT116 cell’s viability. Increasing amounts (20–
80 μM) of apigenin and AP7Glu were used for 
treatment of HCT116 cells. 48 h after treatment 
cell viability was determined by MTT assay. Rela-
tive cell’s viability for cells treated with apigenin 
was calculated as a percentage of HCT116 cells 
viability treated with DMSO that was set as 100 %. 
Relative cell’s viability for cells treated with 
AP7Glu was calculated compared to apigenin. 
Results were presented as the means  SEM of 
at least three independent experiments. P values 
were calculated using Student’s t-test, *p  0.05, 
**p  0.01, ***p ≤ 0.001. 
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AP7Glu induces changes in nuclear  
morphology of HCT116 cells  
Apoptosis is characterized by morpholog-
ical alterations of nuclei, like condensation of 
nuclear chromatin and fragmentation of resid-
ual nuclear structures into apoptotic bodies 
(Lazebnik et al., 1993). DAPI is a dye known 
to form fluorescent complexes with natural 
double-stranded DNA, showing fluorescence 
specificity for AT, AU and IC clusters 
(Kapuscinski and Yanagj, 1979). Therefore, 
DAPI is a good tool for visualization of chro-
matin condensation with fluorescent micros-
copy (Ziegler and Groscurth, 2004). As 
shown in Figure 4A, control group of 
HCT116 cells nuclei were round in shape and 
stained homogeneously with DAPI. In con-
trast, after 48 h treatment of HCT116 cells 
with AP7Glu we have detected formation of 
apoptotic bodies with characteristic nuclear 
morphological changes (Figure 4A, yellow 
arrows). The same effect was detected after 
treatment with apigenin (Figure 4A, yellow 
arrows). In particular, in DMSO treated cells 
we have detected approximately 0,7 % of 
cells undergoing apoptosis (apoptotic bod-
ies), whereas in apigenin and AP7Glu treated 
cells we have detected 12,5 % and 10,5 % of 
apoptotic bodies, respectively. Upon treat-
ment, there was visible decrease in cell num-
ber that correlates with results of MTT assay. 
Furthermore, mitotic cells were not visible 
(Figure 4A). These results suggested that 
treatment of HCT116 cells with AP7Glu, as 
well as with apigenin led to induction of cell 
death. 
 
Treatment of HCT116 cells with AP7Glu 
promote cell death 
HCT116 cells were treated with IC50 con-
centrations of apigenin or AP7Glu for 48 h 
and the proportion of apoptosis and necrosis 
was analyzed using Annexin V/propidium io-
dide staining. Obtained results suggested that 
treatment with AP7Glu led to minor induction 
of apoptosis (approximately 1 % of cells de-
tected in early apoptosis and 2.5 % of cells in 
late apoptosis) (Figure 4B) while 17.5 % of 
cells underwent necrosis (Figure 4B). Treat-
ment of HCT116 cells with apigenin led to the 
same effect, where approximately 1 % of cells 
was detected in early apoptosis, 2.5 % of cells 
in late apoptosis and approximately 14.5 % of 
cells underwent necrosis (Figure 4B). There-
fore, by flow cytometry we confirmed that 
AP7Glu is able to induce cell death. It is im-
portant to point out that AP7Glu displayed the 
same effect in induction of cell death com-
pared to apigenin, but approximately at 4-fold 
lower concentration.  
 
AP7Glu affects apoptosis-associated gene 
expression in HCT166 cells 
In order to investigate whether this cyto-
toxic effect of AP7Glu leads to changes in ex-
pression of molecular markers involved in 
regulation of cell cycle and apoptosis, we in-
vestigated the expression of p53, Bax and Cy-
clin D1 upon treatment with IC50 concentra-
tion of AP7Glu. Furthermore, we analyzed 
the expression of two transcription factors, c-
Myc and SOX9, which expression was shown 
to be deregulated in colon cancer (Chen et al., 
2007; Lü et al., 2008; Matheu et al., 2012). 
Presented results show that treatment of 
HCT116 cells with AP7Glu led to approxi-
mately 1.8-fold induction in Bax expression, 
2-fold induction in p53 expression, while no 
significant changes were observed regarding 
Cyclin D1 and c-Myc gene expression (Figure 
5). In parallel, we investigated the effect of 
apigenin on the expression level of the same 
genes. Similarly to AP7Glu, treatment of 
HCT116 cells with apigenin led to approxi-
mately 2-fold induction in Bax expression, 
2.5-fold induction in p53 expression, while no 
significant changes were observed regarding 
Cyclin D1, c-Myc (Figure 5). Regarding 
SOX9 gene expression upon treatment with 
AP7Glu, we have detected up-regulation of 
its expression of approximately 2.5-fold (Fig-
ure 5) while no significant changes were ob-
served after treatment with apigenin (Figure 
5). 
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DISCUSSION 
Bioactive potential of AP7Glu was ana-
lyzed and compared with apigenin. Obtained 
results demonstrated that sugar moiety in 
AP7Glu had important impact on biological 
activity of apigenin.  
Results on anti-candidal activity are in 
agreement with previous study by Mamada-
lieva et al. (2011) who showed that AP7Glu 
is a more potent growth inhibitor of Candida 
albicans and C. glabrata when compared to 
apigenin. Both compounds had lower inhibi-
tory potential but their fungicidal potential 
can cope with ketoconazole due to drugs pri-
marily static effect. Observations reported 
herein, regarding the influence of apigenin 
and AP7Glu on the cytoplasmic membrane of 
C. albicans, are in accordance with recent 
Figure 4: AP7Glu induces cell death of HCT116 cells. A) Representative composite images showing 
morphological changes of HCT116 cells detected with DAPI staining. Cells were treated with IC50 con-
centrations of apigenin or AP7Glu for 48 h, and imaged by fluorescence microscope. Apoptotic bodies 
formation are marked by yellow arrows. B) Flow cytometry analysis of Annexin-FITC staining and propi-
dium iodide accumulation after treatment of HCT116 cells with apigenin or AP7Glu. Cells were treated 
either with DMSO or corresponding IC50 concetrations (treatment) for 48 h. One representative analysis 
was presented in upper panel. Results of quantitative analyses of PI and Annexin positive cells were 
presented as the means  SEM of at least three independent experiments. P values were calculated 
using Student’s t-test, *p  0.05. Q1: PI+cells; Q2: PI+/Annexin+cells; Q3: PI-/Annexin-cells; Q4: An-
nexin+cells. 
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Figure 5: The effect of apigenin and AP7Glu treatment of HCT116 cells on the expression level of p53, 
Bax, c-Myc, Cyclin D1 and SOX9. Cells were treated with IC50 concentrations of apigenin or AP7Glu for 
48 h and the level of genes expression was quantified by qRT-PCR. Relative gene expression was 
presented as percentage of expression in cells treated with DMSO that was set as 100 %. Results were 
presented as the means  SEM of at least three independent experiments performed in triplicates. P va-
lues were calculated using Student’s t-test. *p  0.05 
 
 
 
studies showing that flavonoids localize ei-
ther in the hydrophobic core of the lipid bi-
layer or at the membrane interface leading to 
corresponding alterations in the membrane 
(Selvaraj et al., 2015). Ketoconazole, com-
mercial antifungal drug that is widely used 
was shown not to have effect on membrane 
structure at tested concentration which is in 
accordance with previous studies (Uno et al., 
1982). Structures of the flavonoids as well as 
their ability to alter the membrane are both 
important factors that influence the nature and 
magnitude of their biological activity (Selva-
raj et al., 2015). AP7Glu caused more disturb-
ances in membrane integrity upon treatment 
of C. albicans cells, which could be attributed 
to difference in chemical structure of the com-
pounds. 
ROS generation by C. albicans is depend-
ent on morphogenesis and their highest levels 
are found in cells with hyphal form. Thus, 
ROS generation plays a major role in tissue 
invasion and infection (Sander et al., 2002). 
Here we demonstrated decreasing amounts of 
extracellular and intracellular ROS in the 
presence of AP7Glu and apigenin which was 
shown to be dose-dependent. We propose that 
ROS inhibition by apigenin and AP7Glu 
could have important influence on the sup-
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pression of fungus pathogenesis, while keto-
conazole does not have significant potential. 
AP7Glu was found to be more effective since 
it caused higher percentage of ROS inhibition 
that could subsequently lead to decreased 
pathogenesis. In addition, both compounds 
exhibited no influence on CYP51 enzyme in-
hibition which is the major target for commer-
cial anticandidal drugs as ketoconazole. Un-
selective nature of ketoconazole CYP51 bind-
ing may be cause of known ketoconazole side 
effects (Lee et al., 2014). By obtained results 
we propose that the major mechanism of anti-
candidal action of AP7Glu and apigenin is re-
lated to cell membrane disruption. In vitro in-
hibition of extra- and intracellular ROS in the 
cells of C. albicans indicated that both com-
pounds may possibly lower the host tissue in-
vasion and accordingly lead to decreased 
pathogenicity of C. albicans. In particular, 
AP7Glu showed higher potential for antimi-
crobial activity. It could inhibit growth of 
tested strains at lower concentration, cause 
membrane disturbance in shorter period of 
time and lead to lower levels of ROS in cells 
of C. albicans, which can contribute to lower 
tissue invasion by this fungi. 
Beside anti-candidal potential we also an-
alyzed cytotoxic effect of both compounds on 
HCT116 cells. Here we present that AP7Glu 
exhibited cytotoxic effect on colon cancer 
cells in vitro, as well as apigenin, by showing 
the ability to reduce cell’s viability and induce 
cell death. Lee et al. (2014) described that 
apigenin effectively inhibits viability of 
HCT116 cells and that treatment with apig-
enin results in chromosomal condensation 
and apoptotic bodies formation. We have 
shown for the first time that AP7Glu treat-
ment of HCT116 cells was even more effec-
tive in reduction of cell’s viability and induc-
tion of cell death. Induction of cell death was 
confirmed by flow cytometry showing that, 
after treatment with AP7Glu, HCT116 cells 
underwent significant necrosis. It has already 
been suggested that apigenin could induce 
apoptosis through p53-dependent pathway 
(Seo et al., 2012) and that cells treated with 
apigenin exert elevated level of p53 and Bax 
(Lu et al., 2010). These results suggest that 
AP7Glu could also induce apoptosis through 
p53-dependent pathway. Moreover, our re-
sults showed that AP7Glu is even more potent 
in inducing apoptosis-associated p53 and Bax 
genes expression in HCT116 cells.  
Interestingly, we have observed different 
effects of AP7Glu vs. apigenin on SOX9 ex-
pression in HCT116 cells. Namely, AP7Glu 
led to increased expression of SOX9 in 
HCT16 cells, while apigenin showed no sig-
nificant effect. The elevated level of SOX9 in 
derivative treated cells opened several ques-
tions. Some authors recognized SOX9 as un-
favorable marker in patients with colorectal 
cancer, observing overexpression in 75 % of 
colorectal adenomas and 83 % of colorectal 
carcinomas (Lü et al., 2008). Considering this 
fact, further upregulation of this gene could be 
an alarming sign of unfavorable effect. On the 
other hand, Bruun et al. (2014) performed tis-
sue microarray analysis of large consecutive, 
population-representative single-hospital se-
ries of primary colorectal carcinomas to ex-
plore the prognostic significance of SOX9 
and could not find prognostic relevance. 
Therefore, further work is needed in order to 
understand the relevance and/or consequence 
of SOX9 induction upon AP7Glu treatment. 
The impact of flavonoids glycosylation on 
different bioactivities is still under intense in-
vestigation; being very complex and rather in-
teresting issue and still requiring more data in 
order to enlighten general influence of sugar 
moieties in bioactivity assays. This is partly 
due to the lack of clinical and in vivo investi-
gations that would support in vitro data. In 
some rarely available clinical trials in vivo 
data differ from that obtained in vitro. Some 
results indicated that glycosylated flavonoids, 
when applied in vivo, had similar or even bet-
ter bioactivities (antidiabetic, antistress, an-
tiallergic, antidegranulating, anti-inflamma-
tory) compared to their respective aglycones 
(Xiao, 2017). Recent findings demonstrated 
that apigenin glucosides appeared to enter 
cancer cells and are effectively hydrolyzed 
within the cells (Srivastava and Gupta, 2009).  
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As natural products, flavonoids are re-
garded as easily obtainable compounds, with 
promising role in cancer chemoprevention or 
agents in clinical antifungal treatment. Fur-
ther study is needed to elucidate the precise 
mechanism of action in colon cancer model 
system for both apigenin and AP7Glu in order 
to apply their safe use.  
 
CONCLUSION 
This study highlighted AP7Glu, deriva-
tive of apigenin, as more biologically potent 
compound when compared with apigenin. 
Presented results indicated its antifungal ac-
tivity comparable to the standard drug keto-
conazole towards all Candida isolates, espe-
cially for fungicidal activity. Also, AP7Glu 
was more prominent in cytotoxic activity on 
colon cancer cells in vitro compared to apig-
enin. 
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